Sign Up to like & get
recommendations!
0
Published in 2018 at "BMJ Case Reports"
DOI: 10.1136/bcr-2017-223252
Abstract: Pembrolizumab is an immune checkpoint inhibitor that significantly improves clinical outcomes in numerous solid organ malignancies. Despite successful therapeutic responses, this new drug comes with a constellation of adverse reactions. Herein, we chronicle the case…
read more here.
Keywords:
toxicities pembrolizumab;
new toxicities;
induced myocarditis;
pembrolizumab induced ... See more keywords